In addition, in a rat model of IBS, intraperitoneal administration of exendin-4 normalized stress-induced defecation and visceral pain sensitivity, without affecting centrally regulated anxiety-like behaviors [56]
Researchers exploring the most effective peptide approaches for fat loss will recognize this as a comprehensive strategy rather than a single-pathway approach
The acquisition brought Blueprint's approved therapy, Ayvakit/Ayvakyt, and an advanced KIT-driven immunology pipeline into Sanofi's holdings
This evolution will be driven by expanded clinical evidence, development of cardiovascular-specific treatment protocols, and modification of reimbursement criteria to include primary prevention of cardiovascular events in high-risk populations regardless of weight loss magnitude
Presented at ADA 86th Scientific Sessions, June 6, 2026